SEGMENT INFORMATION - Profitability (Details) $ in Millions	12 Months Ended
	Oct. 31, 2024 USD ($) segment	Oct. 31, 2023 USD ($) segment	Oct. 31, 2022 USD ($) segment
Segment Reporting [Abstract]
Number of operating segments | segment	3	3	3
Select income statement components
Net revenue	$ 6,510	$ 6,833	$ 6,848
Income from operations	1,488	1,350	1,618
Share-based compensation expense	130	112	126
Depreciation expense	$ 149	$ 128	$ 120
Number of operating segments | segment	3	3	3
Operating Segments
Select income statement components
Income from operations	$ 1,721	$ 1,875	$ 1,857
Segment Reporting, Reconciling Item, Corporate Nonsegment
Select income statement components
Share-based compensation expense	12	0	6
Life Sciences and Applied Markets
Select income statement components
Net revenue	3,215	3,510	3,630
Life Sciences and Applied Markets | Operating Segments
Select income statement components
Net revenue	3,215	3,510	3,630
Income from operations	877	1,049	1,097
Share-based compensation expense	59	60	62
Depreciation expense	64	58	55
Diagnostics and Genomics
Select income statement components
Net revenue	1,651	1,755	1,766
Diagnostics and Genomics | Operating Segments
Select income statement components
Net revenue	1,651	1,755	1,766
Income from operations	320	363	390
Share-based compensation expense	30	28	32
Depreciation expense	56	45	43
Agilent CrossLab
Select income statement components
Net revenue	1,644	1,568	1,452
Agilent CrossLab | Operating Segments
Select income statement components
Net revenue	1,644	1,568	1,452
Income from operations	524	463	370
Share-based compensation expense	29	24	26
Depreciation expense	$ 29	$ 25	$ 22